SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals
ARIA 23.990.0%Feb 17 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: tktom3/12/2016 8:12:25 AM
  Read Replies (1) of 4474
 
Crizotinib sales were $488 million in 2015, is that enough revenue to be shared between three second generation ALK+ compounds that will will treat Crizotinib failures, (Ariad's '113 is one of them), or is Ariad destined to partner soon? With Ariad's cash burn something indeed has to happen.. I'm thinking that Ariad's revenue will be around $50 million in 2017 ( due to part year and ramp up).

The Food and Drug Administration expanded approval of a Pfizer drug to treat a small subset of lung cancer patients with a rare mutation. The agency said on Friday that the drug, Xalkori capsules, was approved for patients with the ROS-1 gene mutation, who make up about 1 percent of patients in the United States with non-small cell lung cancer, the most common form of the disease. The twice-a-day drug is part of a new generation of medications that fight disease by targeting specific genes found in certain patients. It was initially approved in 2011 for another subset of lung cancer patients. Pfizer posted sales for the drug of $488 million in 2015, according its annual report.


Front line is how this would work, but that would be many years out..


http://www.nytimes.com/2016/03/12/business/fda-approves-drug-for-more-lung-cancer-patients.html?_r=1
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News